

Yolande OBADIA, Présidente  
Didier RAOULT, Directeur

Membres Fondateurs :

AIX-MARSEILLE Université  
AP-HM  
Établissement Français du Sang  
Institut MERIEUX – Fondation  
Mérieux  
Institut de Recherche pour le  
Développement  
Service Santé des Armées

Partenaires :

CHU de NICE  
CHU NIMES  
Université de MONTPELLIER



Mme Yolande OBADIA, Présidente du Conseil d'Administration et M. Louis SCHWEITZER, Président du Comité de Recherche, rendent publics la liste des membres du Comité de Recherche et l'appel à candidature pour la direction de l'Institut Hospitalo-Universitaire Méditerranée Infection.

Vous trouverez ci-joints l'appel à candidature pour le poste de directeur ainsi que la composition du Comité de Recherche.

**Call for Application**  
**for the position of Chief Executive Officer (CEO) of the *Institut Hospitalo-Universitaire***  
***Méditerranée Infection*, Marseilles, France, EU**

The French Institute of Infectious and Tropical Diseases - *IHU MEDITERRANEE INFECTION* - based in Marseilles (France) is a Medical and Scientific Cooperation Foundation, research, and innovation operator, established by ministerial decree on November 30, 2011 (Official Journal of the French Republic, December 2, 2011) within the framework of the “Investments for the Future” program.

*IHU MEDITERRANEE INFECTION* founding members are Aix-Marseilles University, *Assistance Publique - Hôpitaux de Marseille* (University Hospitals of Marseilles), *Institut de Recherche pour le Développement* (the French National Research Institute for Development), *Service de Santé des Armées* (French Defence Central Health Service), *Etablissement Français du Sang* (French Blood Agency) and *Institut Mérieux*. The origin of the “*Méditerranée Infection*” project is based on the idea that advances within the field of infectious diseases require to gather laboratory research, epidemiological studies, and patients’ diagnosis and care within a single site. A 27,000 m<sup>2</sup> well-conceived and modern building comprising functional and interactive units opened in 2016, including 75 beds with a BSL-3 Unit and 6,000 m<sup>2</sup> of diagnostic and research laboratories, of which 1,600 m<sup>2</sup> are P3. Following an initial investment of 55M€ for the building’s construction, *IHU MEDITERRANEE INFECTION* has benefited over the last 10 years from more than 40M€ of investments for laboratory research on, and clinical management of patients with infectious diseases. More than 800 staff and trainees are working daily at *IHU MEDITERRANEE INFECTION*, thus creating the conditions for world-class biomedical research and clinical care.

The Institute has focused on the development of novel conceptual and technical strategies to combat infectious diseases, including tropical diseases, integrating prophylactic and therapeutic care, high carat research and biobanking of new microbes, teaching and knowledge dissemination across France and French-speaking countries overseas, especially in Africa– with more than 3,000 students trained during the past ten years.

One of the primary objectives was deconvolution of commensalism, top notch culturomics, mass-spectrometry-based identification, NGS sequencing and high dimensional biobanking of new micro-organisms (including commensals and pathogens, such as bacteria, archae, CRP, giant virus, SARS-CoV-2 isolates...), culminating in the analysis of natural resistance to antibiotics. Innovation and technological transfer has been a key mission for the institute, with 40 patents filed and 9 creations of start-up companies.

*IHU MEDITERRANEE INFECTION* is now launching an open call to recruit a CEO with a full-time position. The selected candidate is expected to take up the position between September 30, 2022 and December 31, 2022. The CEO's clinical activity within the IHU will be conducted on the IHU platform.

The successful candidate must be an eminent researcher, with spectacular achievements in the field of infectious diseases at large, including epidemiology, medicine, immunology, microbiology, and/or virology. An interest in tropical infections would be an asset. In addition, the candidate must have shown organizational leadership, be familiar with research and medical administrative systems in France or elsewhere, and display stellar international reputation. The candidate has to be fluent in both French and English.

Specifically, the successful candidate should have a superb track record of leadership not only in biomedical research, as head of a research laboratory, but also in the management of a large and complex organization, such as a research institute or department. The candidate must have a stainless reputation for effective interpersonal and administrative skills. The CEO must display high-level medical and scientific skills. He or she should also possess strong abilities and experience in establishing, contracts for biomedical research, industrial partnerships and fundraising. The candidate's capacity to federate *IHU Méditerranée Infection* teams around a common project and a bold vision will be a key criterion in the selection process.

Responsibilities include directing and managing the day-to-day operation activities at the IHU (research, care, training), including the oversight of financial, personnel and strategic activities. The successful candidate will oversee the preparation and evaluation of the IHU operating budgets, will supervise grant application and funding, and will supervise the Institute's staff and the recruitment of research teams.

The successful candidate will also serve as the principal liaison to IHU stakeholders: local and national political bodies (Prime Ministry, INSERM, CNRS, IRD), national and international partners, structures or institutions and with the University and the University Hospital of Marseilles (AP-HM). More importantly, the CEO will foster a stimulating, collaborative, and innovative research climate, push for bold and creative lines of research, aiming at establishing the Institute at the highest international level.

The remuneration conditions of the successful candidate will be defined, according to the profile, jointly by *Fondation Méditerranée Infection*, University Aix-Marseilles and University Hospitals of Marseilles.

Candidates should have sent their application to [louis.schweitzer@gmail.com](mailto:louis.schweitzer@gmail.com) by may 31 2022 11:00 AM (Paris time).

### LES MEMBRES DU COMITE DE RECHERCHE

NOM	TITRE
Louis SCHWEITZER	Président du Comité de Recherche Ancien Commissaire Général à l'Investissement,
Professeur Christian BRECHOT	University of South Florida, President du Global Virus Network
Professeur Jean-Laurent CASANOVA	Université Rockefeller et Université de Paris, Directeur du Laboratoire franco-américain de génétique humaine et des maladies infectieuses
Professeur Jacques FELLAY	Médecin spécialisé dans les maladies infectieuses et la génomique humaine CHU Vaudois Lausanne
Professeur Patrick FORTERRE	Institut Pasteur et Paris-Saclay, microbiologiste, virologue, Membre de l'IUF
Professeur Gérard KARSENTY	Directeur du département de génétique et de développement à Columbia University Medical Center
Professeur Bernard MALISSEN	Directeur de recherche au CNRS, membre de l'Académie des Sciences
Professeur Souleymane M'BOUP	Président de l'Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF) Dakar
Professeure Trine MOGENSEN	Département de biomédecine Université d'Aarhus Danemark
Professeur Miroslav RADMAN	Université de Paris Descartes, membre de l'Académie des Sciences
Professeur Alain-Jacques VALLERON	Université Pierre et Marie Curie, membre de l'Académie des Sciences
Professeure Laurence ZITVOGEL	Oncologue clinicienne - Hôpital Gustave Roussy